EMCITATE (RARE THYROID THERAPEUTICS INTERNATIONAL AB): FDA ORIG Approval, Not disclosed in the FDA record.

Key facts

Regulatory context

This application was reviewed under FDA's ORIG submission pathway. A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information. FDA approval of an application does not itself guarantee ongoing marketing; sponsors remain subject to post-approval manufacturing inspections and adverse-event reporting requirements. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

What was approved

FDA's record shows RARE THYROID THERAPEUTICS INTERNATIONAL AB as the sponsor of EMCITATE, with the generic name recorded as unspecified and dosage form TABLET. A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information. This specific application is submission type ORIG (submission number 1) under application number NDA220963, with a submission status date of 20260928. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. This record is drawn directly from FDA's own approvals database rather than from company press materials. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

RARE THYROID THERAPEUTICS INTERNATIONAL AB’s FDA history

Argus HQ has recorded 1 total FDA action tied to RARE THYROID THERAPEUTICS INTERNATIONAL AB: 0 warning letters, 0 recalls, 1 approval record, and 0 Form 483 inspection citations.

Frequently asked questions

What is the FDA application number for this submission?

FDA application number NDA220963, submission 1.

What review priority did FDA assign?

FDA designated this submission as: PRIORITY.

What dosage form is EMCITATE?

EMCITATE is formulated as: TABLET.

What did FDA approve?

FDA's record shows nda approval for EMCITATE (unspecified), dosage form TABLET, sponsored by RARE THYROID THERAPEUTICS INTERNATIONAL AB, under application number NDA220963. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

Related enforcement actions

• Approval (recent): SHANDONG — ANDA approval: SUGAMMADEX SODIUM (unspecified) →
• Approval (recent): PIRAMAL CRITICAL — ANDA approval: DESFLURANE (unspecified) →
• Approval (recent): AUROBINDO PHARMA LTD — ANDA approval: PERAMPANEL (unspecified) →
• Approval (recent): TARO — ANDA approval: LOPERAMIDE HYDROCHLORIDE (unspecified) →
• Approval (recent): LUPIN — ANDA approval: PHYTONADIONE (unspecified) →
• Approval (recent): EVER VALINJECT — NDA approval: Unspecified (unspecified) →
• Approval (recent): GLAND — ANDA approval: LEVOCARNITINE (unspecified) →
• Approval (recent): ABBVIE INC — NDA approval: JUVMO (unspecified) →